Alector, Inc.ALECEarnings & Financial Report
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.
Revenue
$15.3M
Gross Profit
N/A
Operating Profit
$-48.4M
Net Profit
$-42.2M
Gross Margin
N/A
Operating Margin
-315.7%
Net Margin
-275.2%
YoY Growth
68.4%
EPS
$-0.43
Alector, Inc. Q3 FY2024 Financial Summary
Alector, Inc. reported revenue of $15.3M (up 68.4% YoY) for Q3 FY2024, with a net profit of $-42.2M (up 5.1% YoY) (-275.2% margin).
Key Financial Metrics
| Total Revenue | $15.3M |
|---|---|
| Net Profit | $-42.2M |
| Gross Margin | N/A |
| Operating Margin | -315.7% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Alector, Inc. Q3 FY2024 revenue of $15.3M breaks down across 2 segments, led by Gsk at $8.0M (52.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Gsk | $8.0M | 52.1% |
| Abb Vie Biotechnology Limited | $7.3M | 47.6% |
Alector, Inc. Annual Revenue by Year
Alector, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $21.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $21.0M |
| 2024 | $100.6M |
| 2023 | $97.1M |
| 2022 | $133.6M |
Alector, Inc. Quarterly Revenue & Net Profit History
Alector, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.2M | -88.5% | N/A | N/A |
| Q3 FY2025 | $3.3M | -78.8% | $-34.7M | -1063.4% |
| Q2 FY2025 | $7.9M | -47.8% | $-30.5M | -387.7% |
| Q1 FY2025 | $3.7M | -76.9% | $-40.5M | -1101.6% |
| Q4 FY2024 | $54.2M | +257.1% | $-2.1M | -3.8% |
| Q3 FY2024 | $15.3M | +68.4% | $-42.2M | -275.2% |
| Q2 FY2024 | $15.1M | -73.2% | $-38.7M | -256.4% |
| Q1 FY2024 | $15.9M | -4.0% | $-36.1M | -227.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.9M | $15.1M | $15.3M | $54.2M | $3.7M | $7.9M | $3.3M | $6.2M |
| YoY Growth | -4.0% | -73.2% | 68.4% | 257.1% | -76.9% | -47.8% | -78.8% | -88.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $635.5M | $570.7M | $516.0M | $468.3M | $408.3M | $356.4M | $335.3M | $293.2M |
| Liabilities | $456.6M | $420.2M | $397.1M | $341.5M | $313.7M | $285.2M | $277.6M | $262.6M |
| Equity | $178.9M | $150.6M | $118.9M | $126.8M | $94.6M | $71.2M | $57.7M | $30.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-61.3M | $-62.8M | $-50.7M | $-55.0M | $-60.8M | $-49.0M | $-32.5M | $-184.0M |